Related Experiment Video
Updated: Jul 13, 2026
11:31
Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
Published on: August 8, 2012
CHD5 is a tumor suppressor at human 1p36
Anindya Bagchi1, Cristian Papazoglu, Ying Wu
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Cell
|February 10, 2007
Summary
Scientists identified chromodomain helicase DNA binding domain 5 (Chd5) as a tumor suppressor gene. Deletions of this gene in the 1p36 region are linked to various human cancers, offering new therapeutic targets.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Cancer gene discovery often involves analyzing chromosomal gains and losses.
- Deletions in the 1p36 chromosomal region are frequent in diverse human cancers, suggesting the presence of a critical tumor suppressor gene.
- The specific tumor suppressor gene at 1p36 has remained unidentified until now.
Purpose of the Study:
- To functionally identify the tumor suppressor gene located in the 1p36 chromosomal region.
- To investigate the role of the identified gene in tumorigenesis and its mechanism of action.
Main Methods:
- Utilized chromosome engineering to create mouse models with specific gains and losses of the 1p36 region.
- Conducted functional assays to assess the impact of Chd5 on cellular processes like proliferation, apoptosis, and senescence.
- Analyzed the involvement of the p19(Arf)/p53 pathway in Chd5's tumor suppressor activity.
Main Results:
- Functionally identified chromodomain helicase DNA binding domain 5 (Chd5) as a tumor suppressor.
- Demonstrated that Chd5 regulates cell proliferation, apoptosis, and senescence through the p19(Arf)/p53 pathway.
- Provided evidence implicating CHD5 deletion in human cancers.
Conclusions:
- Chd5 acts as a critical tumor suppressor by controlling key cellular processes via the p19(Arf)/p53 pathway.
- The deletion of CHD5 is associated with human tumorigenesis.
- The identification of Chd5 opens new possibilities for developing targeted cancer therapies.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...